Focus: Achieve Life Sciences is a public biotech company focused on small-molecule oncology and smoking cessation therapies. With $13M in cash and $30M in R&D spend (FY 2024), the company is a clinical-stage player pursuing late-phase programs in high-unmet-need areas.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
Achieve is a high-risk/high-reward clinical-stage play with a credible smoking-cessation bet and oncology pipeline, but severe cash constraints and pre-revenue status make this a 2–3 year make-or-break inflection point for job seekers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Achieve Life Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Achieve Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
+2 more
+2 more
+2 more
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors - The Globe and Mail
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors The Globe and Mail
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment - GlobeNewswire
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment GlobeNewswire
Year-long test of quit-smoking pill cytisinicline finds low nausea - Stock Titan
Year-long test of quit-smoking pill cytisinicline finds low nausea Stock Titan
Achieve Life Sciences Closes $354M Financing, Advances Cytisinicline for Smoking & Vaping Cessation with FDA Review in 2026 - Minichart
Achieve Life Sciences Closes $354M Financing, Advances Cytisinicline for Smoking & Vaping Cessation with FDA Review in 2026 Minichart
Verona launch team joins Achieve Life’s bid to launch smoking therapy - Stock Titan
Verona launch team joins Achieve Life’s bid to launch smoking therapy Stock Titan
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma - ChartMill
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma ChartMill
Showing 6 of 10 news items
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Receptor selectivity of cytisinicline: minimal 5-HT3 binding may explain lower incidence of nausea in smoking cessation therapy.
Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials.
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo